Overview
Anal canal carcinoma primarily affects the squamous cells of the anal canal and is most commonly squamous cell carcinoma. It presents diagnostic and therapeutic challenges, particularly in high-risk populations such as individuals living with HIV 1.Diagnosis
Clinical Evaluation: Careful assessment of anal lesions to differentiate benign from malignant conditions 4.
Biopsy: Essential for confirming diagnosis; histopathology and immunohistochemistry crucial for accurate identification, especially for rare entities like anal duct carcinoma 34.
Imaging: CT, MRI, and PET scans used for staging and assessing extent of disease 2.
Endoscopy: May be utilized for direct visualization and biopsy sampling 2.Management
Primary Treatment: Chemoradiation is the mainstay for both perianal and anal canal cancers 2.
Surgical Intervention: Considered for locally recurrent or persistent disease post-primary treatment 2.
Metastatic Disease: Systemic therapy recommended, with treatment protocols updated based on recent clinical data 2.
Follow-Up: Regular clinical evaluations to detect recurrence or persistence, enabling curative-intent retreatment 2.Special Populations
HIV-Positive Individuals: Higher risk of anal carcinoma; screening and treatment of high-grade dysplasia are critical preventive measures 1.
No Specific Recommendations for Pregnancy, Pediatrics, or Elderly: Abstracts do not provide specific guidance for these groups 1234.Key Recommendations
Screen and Treat High-Grade Dysplasia in HIV-Positive Individuals: To significantly reduce the risk of anal carcinoma development (Evidence: Strong 1).
Multidisciplinary Approach for Management: Including gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology for optimal patient care (Evidence: Moderate 2).
Regular Follow-Up Post-Treatment: Essential for detecting recurrence or persistence of disease, facilitating timely curative interventions (Evidence: Moderate 2).References
1 Chromy D, Aigner F, Becker JC, Bickel M, Brunner A, Classen J et al.. German-Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2025. link
2 Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK et al.. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2023. link
3 Lu A, Wu Z, Esebua M, Rao DS. Histologic diagnosis of a case of anal duct carcinoma with cytological correlation and differential diagnoses. Annals of diagnostic pathology 2020. link
4 Crooms JW, Kovalcik PJ. Anal lesions. When to suspect carcinoma. Postgraduate medicine 1985. link